Northern Trust
APGE

Northern Trust’s Apogee Therapeutics APGE Stock Holding History

Northern Trust’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.1M Buy
445,154
+54,275
+14% +$4.89M 0.01% 1101
2026
Q1 		$32.9M Buy
390,879
+63,503
+19% +$4.61M ﹤0.01% 1375
2025
Q4 		$24.7M Buy
327,376
+42,893
+15% +$2.7M ﹤0.01% 1531
2025
Q3 		$11.3M Buy
284,483
+20,295
+8% +$775K ﹤0.01% 2042
2025
Q2 		$11.5M Sell
264,188
-50,290
-16% -$1.91M ﹤0.01% 1988
2025
Q1 		$11.7M Sell
314,478
-12,814
-4% -$495K ﹤0.01% 1942
2024
Q4 		$14.8M Buy
327,292
+20,743
+7% +$1.06M ﹤0.01% 1888
2024
Q3 		$18M Sell
306,549
-4,654
-1% -$223K ﹤0.01% 1683
2024
Q2 		$12.2M Sell
311,203
-13,021
-4% -$632K ﹤0.01% 1877
2024
Q1 		$21.5M Buy
324,224
+147,451
+83% +$6.44M ﹤0.01% 1544
2023
Q4 		$4.94M Buy
176,773
+15,635
+10% +$313K ﹤0.01% 2529
2023
Q3 		$3.43M Buy
+161,138
New +$3.55M ﹤0.01% 2657

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Northern Trust's APGE Position: Q2 2026 in Review

Northern Trust increased its Apogee Therapeutics (APGE) stake by 14% in Q2 2026, buying an estimated $4.89M and bringing the position to 445,154 shares worth $59.1M. The position accounts for 0.01% of the portfolio, ranked #1101.

Northern Trust first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Northern Trust held 445,154 shares of Apogee Therapeutics worth $59.1M as of Q2 2026.
  • Northern Trust bought 54,275 Apogee Therapeutics shares in Q2 2026, an estimated $4.89M.
  • Apogee Therapeutics made up 0.01% of Northern Trust's portfolio in Q2 2026, its #1101 holding.
  • Northern Trust first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.